Secarna Pharmaceuticals and Evotec form strategic partnership
Evotec SE and independent European antisense drug discovery company, Secarna Pharmaceuticals, have formed a strategic partnership in the field of antisense oligonucleotide (ASO)-based therapeutics. Antisense therapy is an innovative, clinically and commercially validated, highly-targeted pharmacological approach which interferes with gene expression in the cells of interest to specifically inhibit the production
